Stem Cell Therapy Unit, Jesús Usón Minimally Invasive Surgery Centre, 10071, Cáceres, Spain.
RICORS-TERAV Network, ISCIII, 28029, Madrid, Spain.
Stem Cell Res Ther. 2023 Jul 28;14(1):187. doi: 10.1186/s13287-023-03413-5.
BACKGROUND: Mesenchymal stromal cells (MSCs) have been shown to exert their therapeutic effects through the secretion of broad spectrum of paracrine factors, including extracellular vesicles (EVs). Accordingly, EVs are being pursued as a promising alternative to cell-based therapies. Menstrual blood-derived stromal cells (MenSCs) are a type of MSC that, due to their immunomodulatory and regenerative properties, have emerged as an innovative source. Additionally, new strategies of cell priming may potentially alter the concentration and cargo of released EVs, leading to modification of their biological properties. In this study, we aimed to characterize the EVs released by MenSCs and compare their therapeutic potential under three different preconditioning conditions (proinflammatory stimuli, physioxia, and acute hypoxia). METHODS: MenSCs were isolated from five healthy women. Following culturing to 80% confluence, MenSCs were exposed to different priming conditions: basal (21% O), proinflammatory stimuli (IFNγ and TNFα, 21% O), physioxia (1-2% O), and acute hypoxia (< 1% O) for 48-72 h. Conditioned media from MenSCs was collected after 48 h and EVs were isolated by a combination of ultra-filtration and differential centrifugation. An extensive characterization ranging from nano-flow cytometry (nFC) to quantitative high-throughput shotgun proteomics was performed. Bioinformatics analyses were used to derive hypotheses on their biological properties. RESULTS: No differences in the morphology, size, or number of EVs released were detected between priming conditions. The proteome analysis associated with basal MenSC-EVs prominently revealed their immunomodulatory and regenerative capabilities. Furthermore, quantitative proteomic analysis of differentially produced MenSC-EVs provided sufficient evidence for the utility of the differential preconditioning in purpose-tailoring EVs for their therapeutic application: proinflammatory priming enhanced the anti-inflammatory, regenerative and immunomodulatory capacity in the innate response of EVs, physioxia priming also improves tissue regeneration, angiogenesis and their immunomodulatory capacity targeting on the adaptive response, while acute hypoxia priming, increased hemostasis and apoptotic processes regulation in MenSC-EVs, also by stimulating immunomodulation mainly through the adaptive response. CONCLUSIONS: Priming of MenSCs under proinflammatory and hypoxic conditions affected the cargo proteome of EVs released, resulting in different therapeutic potential, and thus warrants experimental exploration with the aim to generate better-defined MSC-derived bioproducts.
背景:间充质基质细胞 (MSCs) 通过分泌广泛的旁分泌因子发挥其治疗作用,包括细胞外囊泡 (EVs)。因此,EVs 作为细胞治疗的一种有前途的替代方法正在被研究。月经血源性基质细胞 (MenSCs) 是一种 MSC,由于其免疫调节和再生特性,已成为一种创新来源。此外,细胞预刺激的新策略可能会改变释放的 EVs 的浓度和货物,从而改变其生物学特性。在这项研究中,我们旨在表征 MenSCs 释放的 EVs,并比较它们在三种不同预刺激条件下 (促炎刺激、低氧和急性缺氧) 的治疗潜力。
方法:从五名健康女性中分离出 MenSCs。培养至 80%汇合后,MenSCs 暴露于不同的预刺激条件下:基础 (21% O)、促炎刺激 (IFNγ 和 TNFα,21% O)、低氧 (1-2% O) 和急性缺氧 (<1% O) 48-72 小时。MenSCs 的条件培养基在 48 小时后收集,通过超滤和差速离心的组合分离 EVs。进行了广泛的表征,范围从纳米流式细胞术 (nFC) 到定量高通量 shotgun 蛋白质组学。生物信息学分析用于推导关于其生物学特性的假设。
结果:在预刺激条件之间未检测到释放的 EVs 的形态、大小或数量存在差异。基础 MenSC-EVs 的蛋白质组分析突出显示了它们的免疫调节和再生能力。此外,差异产生的 MenSC-EVs 的定量蛋白质组学分析为通过差异预刺激为其治疗应用定制 EVs 提供了充分的证据:促炎刺激增强了 EVs 固有反应中的抗炎、再生和免疫调节能力,低氧刺激也改善了组织再生、血管生成及其针对适应性反应的免疫调节能力,而急性缺氧刺激通过主要通过适应性反应刺激免疫调节,增加 MenSC-EVs 中的止血和凋亡过程调节。
结论:促炎和缺氧条件下的 MenSCs 预刺激影响释放的 EVs 的货物蛋白质组,导致不同的治疗潜力,因此需要进行实验探索,以生成更明确的 MSC 衍生的生物制品。
Front Cell Dev Biol. 2025-1-27
Cancer Drug Resist. 2024-12-12
World J Stem Cells. 2022-7-26
Nat Rev Immunol. 2023-4